New combo therapy aims to boost immune attack on liver tumors
NCT ID NCT04430452
First seen Jan 08, 2026 · Last updated Jun 22, 2026 · Updated 25 times
Summary
This phase 2 trial tests whether giving the immune-boosting drugs durvalumab (with or without tremelimumab) after radiation therapy can shrink advanced liver cancer that has spread. About 21 adults whose cancer has progressed on or after prior immunotherapy will receive radiation followed by the drugs. The goal is to see if this combination triggers a stronger immune response against the tumor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab (Imfinzi) and tremelimumab (immune-boosting drugs)
What this could lead to
If it works, this could offer a new treatment option for people with advanced liver cancer that has not responded to other immunotherapies.
What could go wrong
This is a small, early-phase trial with only 21 participants. The drugs may cause immune-related side effects, and the combination may not work better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.